Martha Tesfalul1, Kenneth Simbiri, Chikoti M Wheat, Didintle Motsepe, Hayley Goldbach, Kathleen Armstrong, Kathryn Hudson, Mukendi K Kayembe, Erle Robertson, Carrie Kovarik. 1. *University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; †Botswana-University of Pennsylvania Partnership, Gaborone, Botswana; ‡Department of Microbiology, University of Pennsylvania, Philadelphia, PA; §Duke University School of Medicine, Durham, NC; ∥Princess Marina Hospital, Gaborone, Botswana; ¶Division of Plastic & Reconstructive Surgery, University of Toronto School of Medicine, Toronto, Ontario, Canada; #Botswana National Health Laboratory, Gaborone, Botswana; and **Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Abstract
OBJECTIVE: The primary aim of this study was to describe the prevalence of select oncogenic viruses within vulvar squamous cell carcinoma (VSCC) and their association with human immunodeficiency virus (HIV) status in women in Botswana, where the national HIV prevalence is the third highest in the world. METHODS: A cross-sectional study of biopsy-confirmed VSCC specimens and corresponding clinical data was conducted in Gaborone, Botswana. Polymerase chain reaction (PCR) and immunohistochemistry (IHC) viral testing were done for Epstein-Barr virus, human papillomavirus (HPV) strains, and Kaposi sarcoma herpesvirus, and PCR viral testing alone was done for John Cunningham virus. RESULTS: Human papillomavirus prevalence by PCR was 100% (35/35) among tested samples. Human papillomavirus type 16 was the most prevalent HPV strain (82.9% by PCR, 94.7% by either PCR or IHC). Kaposi sarcoma herpesvirus prevalence by PCR had a significant association with HIV status (P = 0.013), but not by IHC (P = 0.650). CONCLUSIONS: The high burden of HPV, specifically HPV16, in vulvar squamous cell cancer in Botswana suggests a distinct HPV profile that differs from other studied populations, which provides increased motivation for HPV vaccination efforts. Oncogenic viruses Kaposi sarcoma herpesvirus and Epstein-Barr virus were also more prevalent in our study population, although their potential role in vulvar squamous cell cancer pathology is unclear.
OBJECTIVE: The primary aim of this study was to describe the prevalence of select oncogenic viruses within vulvar squamous cell carcinoma (VSCC) and their association with human immunodeficiency virus (HIV) status in women in Botswana, where the national HIV prevalence is the third highest in the world. METHODS: A cross-sectional study of biopsy-confirmed VSCC specimens and corresponding clinical data was conducted in Gaborone, Botswana. Polymerase chain reaction (PCR) and immunohistochemistry (IHC) viral testing were done for Epstein-Barr virus, human papillomavirus (HPV) strains, and Kaposi sarcoma herpesvirus, and PCR viral testing alone was done for John Cunningham virus. RESULTS:Human papillomavirus prevalence by PCR was 100% (35/35) among tested samples. Human papillomavirus type 16 was the most prevalent HPV strain (82.9% by PCR, 94.7% by either PCR or IHC). Kaposi sarcoma herpesvirus prevalence by PCR had a significant association with HIV status (P = 0.013), but not by IHC (P = 0.650). CONCLUSIONS: The high burden of HPV, specifically HPV16, in vulvar squamous cell cancer in Botswana suggests a distinct HPV profile that differs from other studied populations, which provides increased motivation for HPV vaccination efforts. Oncogenic viruses Kaposi sarcoma herpesvirus and Epstein-Barr virus were also more prevalent in our study population, although their potential role in vulvar squamous cell cancer pathology is unclear.
Authors: Kenneth O Simbiri; Masanao Murakami; Michael Feldman; Andrew P Steenhoff; Oathokwa Nkomazana; Gregory Bisson; Erle S Robertson Journal: Infect Agent Cancer Date: 2010-03-26 Impact factor: 2.965
Authors: Ralph P Insinga; Kai-Li Liaw; Lisa G Johnson; Margaret M Madeleine Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07 Impact factor: 4.254
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: Jennifer S Smith; Danielle M Backes; Brooke E Hoots; Robert J Kurman; Jeanne M Pimenta Journal: Obstet Gynecol Date: 2009-04 Impact factor: 7.661
Authors: L Stewart Massad; Michael J Silverberg; Gayle Springer; Howard Minkoff; Nancy Hessol; Joel M Palefsky; Howard D Strickler; Alexandra M Levine; Henry S Sacks; Michael Moxley; D Heather Watts Journal: Am J Obstet Gynecol Date: 2004-05 Impact factor: 8.661
Authors: E E Jedy-Agba; E O Dareng; S N Adebamowo; M Odutola; E A Oga; F Igbinoba; T Otu; E Ezeome; F Bray; R Hassan; C A Adebamowo Journal: Cancer Epidemiol Date: 2016-10-22 Impact factor: 2.984
Authors: Tharcisse Mpunga; Ariana Znaor; F Regis Uwizeye; Aline Uwase; Cyprien Munyanshongore; Silvia Franceschi; Gary M Clifford Journal: Int J Cancer Date: 2018-04-26 Impact factor: 7.396
Authors: Tharcisse Mpunga; Marie Chantal Umulisa; Vanessa Tenet; Belson Rugwizangoga; Danny A Milner; Cyprien Munyanshongore; Daniëlle A M Heideman; Maaike C G Bleeker; Massimo Tommasino; Silvia Franceschi; Iacopo Baussano; Tarik Gheit; Felix Sayinzoga; Gary M Clifford Journal: Int J Cancer Date: 2019-06-26 Impact factor: 7.396
Authors: Helena Lucia Barroso Dos Reis; Dennis de Carvalho Ferreira; Neide Aparecida Tosato Boldrini; Carolina Galvão; João Victor Jacomele Caldas; Marize Freitas Santos Neves; Philippe Godefroy Journal: BMC Infect Dis Date: 2019-12-30 Impact factor: 3.090